Want to see GB:SN full AI Analyst Report?
SN Stock Chart & Stats
1140.00 p
29.50 p(2.59%)
At close: 4:00 PM EDT
1140.00 p
29.50 p(2.59%)
Day’s Range― - ―
52-Week Range1,050.00 p - 1,441.50 p
Previous CloseN/A
Volume682.11K
Average Volume (3M)3.93M
Market Cap
£9.73B
Enterprise Value12.80K
Total Cash (Recent Filing)£757.91M
Total Debt (Recent Filing)£3.80B
Price to Earnings (P/E)21.1
Beta1.01
Next Earnings
Feb 23, 2027EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend Yield2.51%
Share Statistics
EPS (TTM)0.76
Shares Outstanding839,857,200
10 Day Avg. Volume2,834,900
30 Day Avg. Volume3,927,868
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.73
Price to Sales (P/S)2.30
P/FCF Ratio16.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,372.29Price Target Upside20.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)1.11
Revenue Forecast (FY)£6.55B
Bulls Say, Bears Say
Bulls Say
Margin Expansion And ProfitabilitySustained margin improvement reflects structural cost efficiency and pricing power. Higher trading and gross margins expand operating leverage, fund R&D and buybacks, and allow management to meet profit targets even with softer top-line, strengthening long-term profitability resilience.
Improving Cash Generation And Free Cash FlowMaterial FCF growth provides durable capital flexibility: supports reinvestment, M&A, share buybacks and dividend growth while keeping leverage manageable. Strong cash conversion across recent years enhances the firm's ability to invest through cycles and maintain shareholder returns.
Product Innovation And Robotics MomentumOngoing launches and robotics adoption expand addressable markets and create durable pull-through for consumables. FDA approvals and increasing CORI utilization deepen clinical adoption, support differentiation versus peers, and underpin medium-term revenue sustainability as utilization rises.
Bears Say
Lowered Revenue Guidance And Soft Top-lineA reduced revenue outlook signals persistent demand headwinds that may limit organic growth for multiple quarters. Reliance on efficiency savings to preserve margins raises execution risk and means topline recovery is a critical dependency for durable earnings and reinvestment plans.
U.S. Orthopaedics Weakness And Portfolio GapsCore orthopaedics underperformance reveals product and commercial gaps in high-margin implants. Delayed set deployments and cementless exposure constrain procedure growth and implant pull-through, making sustainable recovery contingent on product fixes and successful redeployment of sets.
Reimbursement And Payer Headwinds In Wound BioactivesStructural payer/regulatory frictions (CMS changes, prior authorization) reduce predictable volumes and slow channel recovery for wound care bioactives. Persistent reimbursement barriers can depress recurring consumable demand and prolong recovery of a key segment's revenue and margins.
SN FAQ
What was Smith & Nephew plc’s price range in the past 12 months?
Smith & Nephew plc lowest share price was 1050.00 p and its highest was 1441.50 p in the past 12 months.
What is Smith & Nephew plc’s market cap?
Smith & Nephew plc’s market cap is £9.73B.
When is Smith & Nephew plc’s upcoming earnings report date?
Smith & Nephew plc’s upcoming earnings report date is Feb 23, 2027 which is in 201 days.
How were Smith & Nephew plc’s earnings last quarter?
Smith & Nephew plc released its earnings results on Aug 04, 2026. The company reported 0.352 p earnings per share for the quarter, beating the consensus estimate of 0.35 p by 0.002 p.
Is Smith & Nephew plc overvalued?
According to Wall Street analysts Smith & Nephew plc’s price is currently Undervalued.
Does Smith & Nephew plc pay dividends?
Smith & Nephew plc pays a Semiannually dividend of 17.78 p which represents an annual dividend yield of 2.51%. See more information on Smith & Nephew plc dividends here
What is Smith & Nephew plc’s EPS estimate?
Smith & Nephew plc’s EPS estimate is 0.45.
How many shares outstanding does Smith & Nephew plc have?
Smith & Nephew plc has 839,857,200 shares outstanding.
What happened to Smith & Nephew plc’s price movement after its last earnings report?
Smith & Nephew plc reported an EPS of 0.352 p in its last earnings report, beating expectations of 0.35 p. Following the earnings report the stock price went down -6.266%.
Which hedge fund is a major shareholder of Smith & Nephew plc?
Currently, no hedge funds are holding shares in GB:SN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£1,372.29 (20.38% Upside)
£1,372.29 (20.38% Upside)
Insider Transactions
Sold Shares
Worth £53.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.23%
12-Months-Change
Fundamentals
Return on Equity
2.51%
Trailing 12-Months
Asset Growth
6.35%
Trailing 12-Months
Company Description
Smith & Nephew plc
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
SN Stock 12 Month Forecast
Average Price Target
1,372.29 p
▲(20.38% Upside)
Technical Analysis
Advanced Medical Solutions
―
ConvaTec
―
Hikma Pharmaceuticals
―
PureTech Health
―
Spire Healthcare
―









